DoW Tuberous Sclerosis Complex, Idea Development Award

The Tuberous Sclerosis Complex Idea Development Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs as part of the Tuberous Sclerosis Complex Research Program. This program was initiated by Congress to support high-impact biomedical research with strong scientific merit, particularly research that can significantly advance understanding or treatment of tuberous sclerosis complex. The program operates under federal authority and is managed within the Defense Health Agency Research and Development structure. Since its inception, the program has funded numerous projects aimed at improving patient outcomes and expanding scientific knowledge in this specialized field. The purpose of this funding opportunity is to support conceptually innovative and high-impact research that has the potential to lead to critical discoveries in tuberous sclerosis complex research and improvements in patient care. The award emphasizes novel ideas supported by strong preliminary data and a clear scientific rationale. Research may include mechanistic studies, development of animal models, biomarker discovery, therapeutic strategies, and patient-centered studies. Priority areas include neuropsychiatric disorders, tumor prevention and treatment, epilepsy management, diagnostic and therapeutic technologies, and reproductive health impacts associated with the condition. Funding under this opportunity is structured as grants with a maximum total cost of 800000 dollars per award and an anticipated total program funding of approximately 3200000 dollars to support about four awards. The maximum period of performance is three years. Funds may be used for a range of direct and indirect research costs, including limited travel related to collaboration and dissemination of results. However, certain restrictions apply, such as limits on travel expenses and the prohibition of clinical trials. The program does not require cost sharing or matching funds, making it more accessible to a wide range of applicants. Eligibility for the program is broad and inclusive. Both domestic and international organizations may apply, including for-profit and nonprofit entities, public and private institutions, and federal organizations. Principal Investigators must be independent researchers and may apply under either an established investigator category or a new-to-the-field category. Specific eligibility criteria apply to the new-to-the-field option, including limits on prior funding in the subject area and requirements for research commitment. Graduate students and postdoctoral fellows are not eligible to serve as Principal Investigators. Awards are made to organizations rather than individuals. The application process is a two-step submission requiring a pre-application and a full application. The pre-application consists of a letter of intent submitted through the Electronic Biomedical Research Application Portal. The full application must be submitted through either Grants.gov or eBRAP depending on the applicant organization type. Required application components include a project narrative, supporting documentation, abstracts, statements of work, impact and innovation statements, and additional documentation such as letters of support and research plans. The process requires strict adherence to formatting and submission guidelines, and failure to comply may result in rejection. Applications undergo a two-tier review process consisting of peer review and programmatic review. Peer review evaluates scientific merit based on criteria such as impact, research strategy, feasibility, innovation, and personnel qualifications. Programmatic review considers relevance to program priorities, portfolio balance, and potential military or public benefit. Additional considerations include data sharing plans, budget appropriateness, and institutional support. Funding decisions are contingent upon available funds and overall application quality. The timeline for this funding opportunity includes a pre-application deadline of July 23, 2026 and a full application deadline of August 6, 2026. Peer review is expected in November 2026, followed by programmatic review in February 2027. Awards are anticipated to be made by September 30, 2027. The funding opportunity is part of an annual program cycle, and future opportunities are expected based on congressional appropriations. Applicants are encouraged to begin preparation early due to the complexity of submission requirements and registration processes.

Focus heavily on high-impact outcomes and strong preliminary data; ensure rigorous study design and feasibility; clearly articulate both short-term and long-term impact; align closely with specified focus areas